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Background: Persons living with HIV (PLWH) are disproportionately burdened with methicillin-resistant
Staphylococcus aureus (MRSA). Our objective was to evaluate prevalence and risks for MRSA colonization
in PLWH.
Methods: Adults were recruited from Johns Hopkins University AIDS Service in Baltimore, Maryland. A risk
questionnaire and specimen collection from anatomic sites with culture susceptibility and genotyping
were completed. Generalized estimating equation modeling identiﬁed MRSA colonization risk factors.
Results: Of 500 participants,mostwere black (69%), on antiretroviral therapy (ART) (87%),with undetectable
viral loads (73.4%). Median CD4 count was 487 cells/mm3 (interquartile range, 316-676.5 cells/mm3). MRSA
prevalence was 15.4%, predominantly from the nares (59.7%). Forty percent were nares negative but were
colonized elsewhere. Lower odds for colonizationwere associated with recent sexual activity (adjusted odds
ratio [AOR]¼0.84,P< .001)andART (AOR¼0.85,P¼ .011). Increasedoddswereassociatedwith lower income
(<$25,000 vs >$75,000; AOR ¼ 2.68, P < .001), recent hospitalization (AOR ¼ 1.54, P < .001), incarceration
(AOR ¼ 1.55, P < .001), use of street drugs (AOR¼ 1.43, P < .001), and skin abscess (AOR¼ 1.19, P < .001).
Conclusions: Even with high MRSA prevalence, the proportion identiﬁed through nares surveillance
alone was low, indicating the importance of screening multiple anatomic sites. Associations were not
found with same-sex coupling or black race. MRSA prevention might be a beneﬁt of ART in PLWH.
Copyright  2015 by the Association for Professionals in Infection Control and Epidemiology, Inc.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Methicillin-resistant Staphylococcus aureus (MRSA) continues to
cause excess morbidity and mortality among persons living with
HIV (PLWH). In the United States, PLWH have substantially higher
incidence of MRSA infections than the general population (12.3/
1,000 person years compared with 1-2/1,000 person years),1 and
MRSA remains a substantial reason for hospital admission.2
Metropolitan areas throughout the country have documented a
substantial increase inMRSA infections,3-5 peaking in 2008, with an
incidence 5 times greater in PLWH than HIV-uninfected persons
within a large health care system.6 Despite recent reported declines
in skin and soft tissue infection, PLWH continue to shoulder a
disproportionate burden of disease.7
Key risk factors for MRSA colonization and infection have been
identiﬁed as a result of these data and include substance
abuse8,9; high-risk sexual practices in persons with greater
numbers of sex partners, regardless of sexual orientation10; and
having a sexual partner with a known skin infection.10 Additional
risks for MRSA infection among PLWH include male sex,7
incarceration history,7 lower CD4 counts,4,5,10 high viral load,4,11
recent hospital admission,12 b-lactam antibiotic use,3 lack of
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cotrimoxazole prophylaxis,5,11 and known MRSA infection in the
last 12 months.3
Despite recent attention to this issue, many questions related to
the HIV-MRSA interface remain unanswered. To further understand
risk and enable the improvement of this population’s health and
well-being and limit the spread of MRSA within and among part-
ners, this study assessed the overall prevalence of MRSA coloniza-
tion at multiple body sites among PLWH and their primary
partners. In addition, we determined the risk factors that are
associated with MRSA colonization.
METHODS
Study setting and participant selection
To assess colonization prevalence among PLWH, we conducted a
cross-sectional epidemiologic evaluation of MRSA among persons
within the Johns Hopkins University AIDS Service (JHUAS). The
JHUAS is a hospital-based practice that provides specialty care at
the Moore Clinic on the Johns Hopkins Hospital campus in down-
town Baltimore, Maryland, and at Green Spring Station (GSS) in
Baltimore County. Urban Baltimore has a high incidence of HIV
infection andMRSA colonizationwithin outpatient populations.13,14
Greater than 50% of our clients reside in East Baltimore and >75%
are within the city limits. The Moore Clinic follows an average of
2,000 clients annually, including the uninsured, with most residing
in Baltimore City. Most are black (77%), with major HIV trans-
mission risks of intravenous drug use and heterosexual sex. Colo-
cated services include viral hepatitis clinic, counseling, case
management, social work, laboratory services, wound care, and an
outpatient pharmacy. The GSS medical ofﬁce serves a smaller pa-
tient cohort (n ¼ 650) that is primarily white (64%), with a greater
proportion residing in Baltimore’s surrounding counties. The major
HIV transmission risk at GSS is men who have sex with men. The
GSS Clinic also provides services to persons without HIV infection
and does not accept the uninsured. There is an onsite laboratory
and outpatient pharmacy. Many providers work at both the GSS
and Moore Clinic locations.
Sample size calculations were informed by previous work
showing a strong association between MRSA and previous or cur-
rent abscess15 along with community prevalence data for Baltimore
City. Based on the projected probability of MRSA among persons
with abscess (0.30) and the probability of abscess in the entire
cohort (0.18), a sample size of 500 was needed to obtain 90% power
at a ¼ 0.05 for a 2-tailed test. This sample size would allow us to
detect associations between having a current abscess and MRSA
colonization.
Subjects were recruited from March 1, 2010-June 30, 2010, with
microbiologic analysis completed in April 2011. Eligible primary
subjectswere adultmen andwomen ages18 yearswith the ability
to read or understand spoken English who receive care within the
JHUAS. Potential participants were approached and screened
consecutively during the recruitment period: every tenth patient
entering the Moore Clinic and all patients at GSS. We gathered
specimens from sexual partners to examine similarities and differ-
ences between partners and MRSA colonization. Sexual partners
were eligible for inclusion if referred by the index HIV-positive
subject, regardless of the partner’s HIV status. Participants were
offered a $25 gift card for participation. The study was approved by
the Johns Hopkins Medicine Institutional Review Board.
Collection of clinical specimens
A total of 6 swabs for men and 7 for womenwere collected, plus
an additional swab for anyone with a wound. Anterior nares,
axillary, throat, groin, perineum, and rectal swabs were obtained
using BactiSwab II dual-headed culturettes (Remel, Lenexa, KS). The
perineum is the area between the anus and scrotum or vulva.
Vaginal swabs were collected on both women and postoperative
transgendered women. Wound specimens were obtained from any
patient presenting with an open or draining wound. Two trained
registered nurses collected all patient swabs. All swabs were
collected during the clinic visit at study enrollment, transported at
room temperature, and stored at 5C until processing within
24 hours of collection.
Risk factor evaluation
A survey instrument was designed with a set of questions used
in a questionnaire previously implemented within the same pop-
ulation to assess factors related to a person’s hospital and com-
munity risks for MRSA acquisition. Another 13 questions were
added to assess behavioral risk factors, leading to a 64-item ques-
tionnaire. The current study did not evaluate all 64 items. A study
team member administered the questionnaire face-to-face during
the clinic visit at study enrollment. Interviewers were trained in
sexual history taking and pilot tested the survey instrument. In-
terviews were conducted in a private setting, and conﬁdentiality of
responses was ensured to address the tendency for subjects to
provide socially desirable responses. Both clinic populations are
routinely screened for sexually history and sexually transmitted
infections at each clinic visit. The time frame for any sexual activity
or drug use was the 12 months prior to the interview. Medical re-
cords were reviewed by research nurses for clarity of HIV-related or
sexual history, comorbidities, admission data, and other self-
reported information from the questionnaire. Information from
medical records was used if discrepancies occurred with self-
reported information.
Microbiologic evaluation
Using standard culture methods, a swab was streaked onto
CHROMagar MRSA (BD Diagnostics, Sparks, MD) [CHROM-MRSA], a
selective medium, and then placed in Trypticase soy broth with
6.5% NaCl. Gram-positive cocci that were catalase positive and latex
agglutination positive were identiﬁed presumptively as S aureus.
The presumptive S aureus isolates recovered from the enrichment
broth were subbed and sent to the BD Phoenix Automated Micro-
biology System (BD Diagnostics, Sparks, MD)16 for identiﬁcation
and susceptibility testing when the matching CHROM-MRSA agar
plates were negative. All isolates growing on CHROM-MRSA were
considered MRSA.
Staphylococcal genotyping was performed using the Ibis
Staphylococcus Typing and Characterization kit (Ibis Biosciences,
Carlsbad, CA). This multiplex, broad-based, molecular assay, per-
formed in a microtiter plate format, uses primer sets that are
capable of identifying S aureus (tufB and nuc) and distinguishing
MSSA from MRSA (mecA). It also incorporates primers that deter-
mine the presence of Panton-Valentine leukocidin genes (LukS and
LukD), toxic shock toxin 1 (TSST1), and high-level (mupA) and
low-level (ileS) mupirocin resistance. Strain characterization is
performed by multilocus sequence typing using a unique set of
sequences from 7 common housekeeping genes for S aureus. The
assay is based on the principle of polymerase chain reaction
(PCR)eelectrospray ionization mass spectrometry (ESI-MS) and is
performed on the Ibis T5000 instrument (Ibis Biosciences, Carlsbad,
CA).17,18 The assay was performed according to the manufacturer’s
instructions and interpreted according to the guidelines in the
reference by Wolk et al.18
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Table 1
Summary statistics of study measures
Characteristics
Overall sample
(N ¼ 500)
Green Spring Station (n ¼ 150) Moore Clinic (n ¼ 350)
MRSA negative
(n ¼ 136)
MRSA positive
(n ¼ 14)
MRSA negative
(n ¼ 287)
MRSA positive
(n ¼ 63)
Sex
Male 330 (66.0) 113 (83.1) 13 (92.9) 173 (60.3) 31 (49.2)
Female 170 (34.0) 23 (16.9) 1 (7.1) 114 (39.7) 32 (50.8)
Race
Black 345 (69.0) 36 (26.5) 3 (21.4) 254 (88.5) 52 (82.5)
Other 13 (2.6) 7 (5.2) 1 (7.1) 4 (1.4) 1 (1.6)
White 142 (28.4) 93 (68.4) 10 (71.4) 29 (10.1) 10 (15.9)
Education
No high school or GED 131 (26.2) 0 (0) 0 (0) 103 (35.9) 28 (44.4)
High school or GED 143 (28.6) 14 (10.3) 2 (14.3) 109 (38.0) 18 (28.6)
Some college-vocational 111 (22.2) 42 (30.9) 5 (35.7) 52 (18.1) 12 (19.1)
College graduate or more 115 (23.0) 80 (58.8) 7 (50.0) 23 (8.0) 5 (7.9)
Yearly income
<$25,000 351 (70.5) 24 (17.9) 3 (21.4) 264 (92.0) 60 (95.2)
$25,001-$50,000 62 (12.5) 37 (27.6) 6 (42.9) 17 (5.9) 2 (3.2)
$50,001-$75,000 46 (9.2) 36 (26.9) 3 (21.4) 6 (2.1) 1 (1.6)
>$75,000 39 (7.8) 37 (27.6) 2 (14.3) 0 (0) 0 (0)
Been arrested
Yes 40 (8.0) 4 (2.9) 0 (0) 26 (9.1) 10 (15.9)
No 460 (92.0) 132 (97.1) 14 (100) 261 (90.9) 53 (84.1)
Hands-on customer contact job
Yes 94 (18.8) 49 (36.0) 4 (28.6) 39 (13.6) 2 (3.2)
No 406 (81.2) 87 (64.0) 10 (71.4) 248 (86.4) 61 (96.8)
Sexual orientation
Different sex 315 (63.0) 95 (69.9) 8 (57.1) 69 (24.0) 13 (20.6)
Same sex-both sexes 185 (37.0) 41 (30.1) 6 (42.9) 218 (76.0) 50 (79.4)
Substance abuse (yes to street drugs)*
Yes 253 (50.6) 31 (22.8) 4 (28.6) 173 (60.3) 45 (71.4)
No 247 (49.4) 105 (77.2) 10 (71.4) 114 (39.7) 18 (28.6)
Sexually active*
Yes 336 (67.2) 111 (81.6) 11 (78.6) 177 (61.7) 37 (58.7)
No 164 (32.8) 25 (18.4) 3 (21.4) 110 (38.3) 26 (41.3)
No. of sex partners in last 30 d
0 220 (44.3) 50 (36.8) 4 (28.6) 133 (46.3) 33 (52.4)
1 240 (48.3) 70 (51.5) 7 (50.0) 135 (47.0) 28 (44.4)
2 37 (7.4) 16 (11.8) 3 (21.4) 16 (5.7) 2 (3.2)
STIy
Yes 16 (3.2) 8 (5.9) 1 (7.1) 6 (2.1) 1 (1.6)
No 484 (96.8) 128 (94.1) 13 (92.9) 281 (97.9) 62 (98.4)
Current abscess
Yes 39 (7.8) 9 (6.6) 2 (14.3) 22 (7.7) 6 (9.5)
No 461 (92.2) 127 (93.4) 12 (85.7) 265 (92.3) 57 (90.5)
Prior abscess*
Yes 67 (13.4) 16 (11.8) 2 (14.3) 38 (13.2) 11 (17.5)
No 433 (86.6) 120 (88.2) 12 (85.7) 249 (86.8) 52 (82.5)
Hospitalized*
Yes 142 (28.5) 25 (18.4) 2 (14.3) 85 (29.7) 30 (47.6)
No 357 (71.5) 111 (81.6) 12 (85.7) 201 (70.3) 33 (52.4)
On isolationz
Yes 86 (17.3) 17 (12.8) 2 (14.3) 55 (19.2) 12 (19.0)
No 410 (82.7) 116 (87.2) 12 (85.7) 231 (80.8) 51 (81.0)
HIV medication
Yes 430 (86.7) 125 (92.6) 14 (100) 242 (84.9) 49 (79.0)
No 66 (13.3) 10 (7.4) 0 (0) 43 (15.1) 13 (21.0)
On prophylaxisx
Yes 86 (17.3) 11 (8.1) 0 (0) 59 (20.8) 16 (25.4)
No 411 (82.7) 125 (91.9) 14 (100) 225 (79.2) 47 (74.6)
Viral load
Undetectable 367 (73.4) 115 (84.6) 14 (100.0) 196 (68.3) 42 (66.7)
Detectable 133 (26.6) 21 (15.4) 0 (0) 91 (31.7) 21 (33.3)
CD4 count
<200 58 (11.6) 5 (3.7) 0 (0) 42 (14.6) 11 (17.5)
201-350 92 (18.4) 20 (14.7) 0 (0) 55 (19.2) 17 (27.0)
351-500 113 (22.6) 27 (19.9) 6 (42.9) 69 (24.0) 11 (17.4)
>500 237 (47.4) 84 (61.8) 8 (57.1) 121 (42.2) 24 (38.1)
NOTE. Values are n (%). Missing: hospitalized (n ¼ 1), isolation (n ¼ 4), prophylaxis (n ¼ 3), income (n ¼ 2), HIV medication (n ¼ 4), and number of sex partners in 30 days
(n ¼ 3).
GED, General Educational Development; MRSA, methicillin-resistant Staphylococcus aureus; STI, sexually transmitted infection.
*Within previous 12 months.
yWithin previous 6 months.
zOn any type of isolation during any previous hospitalization.
xProphylaxis for HIV-associated opportunistic infections includes any use of trimethoprim-sulfamethoxezole, dapsone, azithromycin, or ﬂuconazole.
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Statistical methods
Descriptive statistics were computed on all study variables.
Frequency distributions were used to summarize categorical vari-
ables, and measures of central tendency and dispersion were used
to summarize continuous variables. Statistical models were con-
structed to model MRSA status as a function of demographic,
behavioral, and clinical characteristics. Because between-site dif-
ferences in this multisite study were substantial, we accounted for
them with the implementation of generalized linear models with
an unknown within-site correlation structure. Model parameters
were estimated using generalized estimating equations (GEEs).
Bivariate associations between all variables and the outcome of
MRSA status were examined in unadjusted GEE models. A
multivariable-adjusted model was chosen based on clinical rele-
vance, statistical signiﬁcance, and quasi-likelihood under the in-
dependence model criterion. Odds ratios (ORs) and 95% conﬁdence
intervals (CIs) were reported. The data analysis was generated using
SAS software version 9.3 of the SAS System for Windows (SAS
Institute, Cary, NC).
RESULTS
Study population characteristics
Table 1 lists the characteristics of the participants in the study.
All were HIV positive. Of those participating, most (87%) were on
HIV medications. Participants’ median CD4 count was 487 cells/
mm3 (interquartile range, 316-676.5 cells/mm3), with 11.6%
(n ¼ 58) enrolled with a CD4 count <200 cells/mm3; most (73.4%;
n ¼ 367) had an undetectable viral load at enrollment.
Of the study’s 500 participants, 66% were men and 69% were
black. Although most participants had received at least a high
school education (74%), most (71%) also had an annual income of
<$25,000. Over half of the participants reported sexual activity
within the previous 12 months (67%). Almost two-thirds identiﬁed
as heterosexual (63%).
Isolate characteristics
A total of 217 MRSA isolates from 77 individuals were identiﬁed
and characterized with PCR ESI-MS technology. Of those, 86.2%
were identiﬁed as a USA 300 strain type. The remaining 13.8% of the
isolates included strain types USA 100, 700, 900, 1000, and 200/
1100. The rates for Panton-Valentine leukocidin (PVL) genes (LukS
and LukD), TSST1, and high-level (mupA) mupirocin resistancewere
77.4%, 5.1%, and 2.8%, respectively. No isolates exhibited low-level
(IleS) mupirocin resistance. All isolates positive for both mupir-
ocin resistance and PVL were identiﬁed as USA 300 strain type,
whereas the TSST1 positive isolates were amix of both USA 300 and
USA 100 strains. Of all 217 MRSA isolates from the 77 individuals,
the proportions were highest for the nares (21.2%) and throat
(20.7%), followed by the rectum (16.1%), groin (15.2%), perineum
(15.2%), vagina (5.1%), axilla (4.1%), and wound (2.3%).
MRSA colonization by body site
Among 77 individuals with MRSA colonization (15.4% preva-
lence), the most common anatomic sites were nares of 46 in-
dividuals (59.7%) and throat of 45 individuals (58.4%) (Table 2).
Forty eight (62.3%) of those colonized were culture positive at >1
site, and only 1 individual was colonized with multiple strain types.
Thirty-one individuals (40.3%) were culture negative from the nares
but were found to be colonized with MRSA at another anatomic
site. Among those with MRSA colonization, the number colonized
at only 1 site was 29 (37.7%), whereas 20 were colonized at 2-3 sites
(26.0%), 22 were colonized at 4-5 sites (28.6%), and 6 individuals
were colonized at6 sites (7.8%). Two-sided Fisher exact tests were
performed to examine associations between MRSA colonization
sites and sexual activity in the prior 12 months and found not to be
associated with the throat (P ¼ .318), perineum (P ¼ .563), groin
(P ¼ .702), vagina (P¼ .533), or rectum (P¼ .850). The prevalence of
USA300 strains was high across all body sites, ranging from 81.8%
for vaginal sites and up to 94.1% (n ¼ 32) for rectal sites. All 5
wounds colonized with MRSA were USA300 strains.
Sex partners screening and MRSA status
We obtained data on 34 dyads (n ¼ 68) to examine similarities
and differences between partners and MRSA colonization. Ten
couples (29%) had at least 1 partner who was colonized with MRSA
in at least 1 body site. Four of the 10 couples were both partners
positive for MRSA. All 4 of these subject-partner pairs (100%)
shared the same strain type, and all were identiﬁed as USA 300 by
PCR ESI-MS technology. Only 1 of the 4 MRSA-positive concordant
couple was positive for colonization in several body sites: a woman
was positive for vaginal, rectal, perineum, and groin, whereas her
male partner was positive for the axilla and throat. The remaining 3
couples had the female partner positive at 1 body site (nares in 2,
vaginal in 1), whereas the male partner was positive at multiple
sites.
Risk factors for MRSA colonization
Unadjusted and multivariable models are presented in Table 3.
In the unadjusted model, persons with the lowest annual income
(<$25,000) had the greatest odds of colonization compared with
those with the highest income (>$75,000) (OR¼ 3.96; 95% CI, 3.61-
4.32). In the adjustedmodel, these relationships remained, but they
were somewhat attenuated. Compared with the highest income
(>$75,000), persons earning <$25,000 had 2.68 odds of coloniza-
tion (95% CI, 2.33-3.08). Including race and income in the GEE
model resulted in multicollinearity between the 2 variables.
Further, the 1.13 odds of colonization among African Americans
relative to Caucasians was not signiﬁcant (95% CI, 0.67-1.90);
therefore, race was removed from the ﬁnal model.
Lower adjusted odds of colonization were associated sexual
activity in the previous 12 months and use of highly active anti-
retroviral therapy. Participants who reported being sexually active
within the prior 12 months had lower odds of MRSA colonization
(adjusted odds ratio [AOR] ¼ 0.84; 95% CI, 0.83-0.85). Taking HIV
medication was associated with lower odds of MRSA colonization
(AOR ¼ 0.85; 95% CI, 0.75-0.96). In the unadjusted analysis, men
Table 2
MRSA prevalence among body sites by nares result
Positive
body site
Nares negative
(n ¼ 454)
Nares positive
(n ¼ 46)
Total positive
(n ¼ 77)
USA300 positive*
(n ¼ 66)
Nares NA NA 46 (59.7) 39 (84.8)
Throat 15 (3.3) 30 (65.2) 45 (58.4) 37 (82.2)
Rectal 11 (2.4) 23 (50.0) 34 (44.2) 32 (94.1)
Groin 9 (2.0) 24 (52.2) 33 (41.6) 28 (84.8)
Perineum 6 (1.3) 26 (56.5) 32 (42.9) 29 (90.6)
Axilla 1 (0.2) 8 (17.4) 9 (11.7) 8 (88.9)
Woundy 1 (3.2) 4 (66.7) 5 (13.5) 5 (100)
Vaginalz 4 (2.6) 7 (36.8) 11 (6.5) 9 (81.8)
NOTE. Values are n (%).
MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable.
*Percent of USA300 positive out of total positive for each body site.
yTotal of 37 individuals with a wound: 31 nares negative and 6 nares positive.
zTotal of 170 women: 152 nares negative and 19 nares positive.
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were less likely to be colonized with MRSA than women (AOR ¼
0.61; 95% CI, 0.52-0.71); however, this relationship did not remain
in the ﬁnal adjusted model (AOR ¼ 0.75; 95% CI, 0.53-1.05).
Additional risks for MRSA were conferred for several attri-
butes. Those who had been arrested were 55% more likely to have
MRSA colonization (AOR ¼ 1.55; 95% CI, 1.34-1.80). Using street
drugs in the previous 12 months conferred independent addi-
tional risk for MRSA infection (AOR ¼ 1.343; 95% CI, 1.38-1.48).
Participants with a history of abscess, with a current abscess
(AOR ¼ 1.19; 95% CI, 1.17-1.20), or having been hospitalized
(AOR ¼ 1.54; 95% CI, 1.22-1.94) were also signiﬁcantly more likely
to be colonized with MRSA.
DISCUSSION
MRSA is a preventable infection that can lead to signiﬁcant
morbidity and mortality among PLWH. The ﬁndings from the pre-
sent study provide new information about risk factors for MRSA
colonization and are particularly relevant to the ongoing debate
regarding body site colonization and sexual acquisition among this
vulnerable population. Colonization of the groin in particular has
been associated with skin and soft tissue infections,19 suggesting
the importance of the anatomic site of colonization in setting sur-
veillance and treatment priorities. In the present study, we found
that 40.3% of all MRSA-colonized individuals were culture negative
Table 3
GEE model results
Characteristics
Unadjusted model Adjusted model
OR (95% CI) P value OR (95% CI) P value
Sex
Male 0.61 (0.52-0.71) <.0001 0.75 (0.53-1.05) .0888
Female Reference Reference
Education
No high school or GED 2.34 (1.40-3.93) .0013
High school or GED 1.33 (0.80-2.21) .2690
Some college-vocational 1.57 (1.38-1.80) <.0001
College graduate or more Reference
Yearly income
<$25,000 3.96 (3.61-4.35) <.0001 2.68 (2.33-3.08) <.0001
$25,001-$50,000 2.82 (2.37-3.37) <.0001 2.50 (1.87-3.32) <.0001
$50,001-$75,000 1.76 (1.32-2.34) .0001 1.67 (1.35-2.06) <.0001
$75,001 Reference
Been arrested
Yes 2.07 (1.92-2.23) <.0001 1.55 (1.34-1.80) <.0001
No Reference Reference
Hands-on customer contact job
Yes 0.33 (0.17-0.66) .0017
No Reference
Sexual orientation
Different sex 1.73 (1.16-2.58) .0077
Same sex-both sexes Reference
Substance abuse (yes to street drugs)*
Yes 1.69 (1.38-2.07) <.0001 1.43 (1.38-1.48) <.0001
No Reference Reference
Sexually active*
Yes 0.74 (0.60-092) .0027 0.84 (0.83-0.85) <.0001
No Reference Reference
No. of sex partners in last 30 d
0 1.22 (1.15-1.28) <.0001
1 Reference
2 0.95 (0.47-1.90) .8819
Current or prior abscessy
Yes 1.44 (1.09-1.91) .0109 1.19 (1.17-1.20) <.0001
No Reference Reference
Hospitalized*
Yes 1.91 (1.51-2.43) <.0001 1.54 (1.22-1.94) .0003
No Reference Reference
HIV medication
Yes 0.66 (0.54-0.80) <.0001 0.85 (0.75-0.96) <.0108
No Reference Reference
On prophylaxisz
Yes 1.20 (1.08-1.33) .0009
No Reference
CD4 count
<200 1.36 (1.22-1.52) <.0001
201-350 1.46 (1.03-2.06) .0329
351-500 1.16 (0.61-2.19) .6556
>500 Reference
NOTE. Missing: hospitalized (n ¼ 1), prophylaxis (n ¼ 3), income (n ¼ 2), and HIV medication (n ¼ 4). Nonsigniﬁcant univariate results: race, on any type of isolation during
hospitalization, and undetectable viral load. Nonsigniﬁcant multivariate analysis: sexual orientation, race, CD4 count, prophylaxis, number of sex partners, hands-on job, and
education.
CI, conﬁdence interval; GED, General Educational Development; GEE, generalized estimating equation; MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio.
*Previous 12 months.
yAbscess groups combined to be current or history of abscess (yes/no). Reference group was no.
zProphylaxis for HIV-associated opportunistic infections includes any use of trimethoprim-sulfamethoxezole, dapsone, azithromycin, or ﬂuconazole.
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in the nares, suggesting that surveillance of the nares alone can
miss substantial MRSA colonization among PLWH and may
contribute to both transmission in hospital and community
settings.
Being sexually active in the previous 12 months was found to
lower the odds of MRSA colonization, suggesting that other
means of acquisition may play a greater role in transmission in
our study population. Comparing those reporting sexual activity
with sexually inactive individuals, we found signiﬁcant differ-
ences (P ¼ .041) in the proportion with CD4þ T cell counts >500
(50.3 vs 41.5, respectively) and <200 (10.1 vs 14.6, respectively).
Consequently, sexually active individuals may be in better overall
health, therefore providing one possible explanation of the pro-
tective effect of this characteristic. Four of the 10 sexual partner
pairs were found to carry the same strain, indicating likely
household transmission.
Although several recent studies report increased MRSA trans-
mission among men who have sex with men populations,3,4,6 we
did not ﬁnd an association with same-sex coupling when adjusting
for other risk factors. The loss of a signiﬁcant association may have
been a consequence of confounding by other factors. Two-sided
Fisher exact tests were performed to examine associations with
sexual orientation. Compared with heterosexual orientation, those
reporting same or both sex orientation were more likely to be
sexually active (76.8% vs 61.1%, P ¼ .001) and report an annual in-
come >$75,000 (16.9% vs 8%, P < .001), both of which were pro-
tective in adjusted analysis. Compared with same or both sex
orientation, heterosexual orientation was positively associated
with substance abuse (29.2% vs 11.9%, P < .001) and being hospi-
talized (32.2% vs 22.2%, P< .010) or arrested (10.1% vs 4.3%, P< .025)
in the previous 12 months, which were risks for colonization in
adjusted analysis. Lack of association in multivariate analysis for
multiple sex partners may be inﬂuenced by low prevalence (n¼ 37,
7.4%) and underreporting related to social desirability bias. Age and
race were not associated with increased MRSA colonization.
Use of HIV antiretroviral therapy (ART) lowered the odds of
MRSA colonization. Although several studies have looked at use of
ART as a risk factor for MRSA,21 3 of the 4 studies that found any
association did so only in univariate analyses.20,22,23 Only 1 study
showed signiﬁcance in a multivariate analysis, with a reduced odds
of MRSA infection when taking ART.11 Our ﬁndings suggest that
receiving ART may lower the odds of colonization as well.
Clinical indicators of immune status, viral load, and CD4 count
were not found to be signiﬁcantly associated with MRSA coloni-
zation. It may be that being on ART was a surrogate indicator of
greater engagement in outpatient primary care and fewer en-
counters with hospitals and other acute health care settings where
contact with and transmission of MRSA can occur. Greater
engagement in primary care, which enhances primary prevention,
may be protective of MRSA colonization regardless of the stage of
HIV disease.
Studies of MRSA surveillance within general populations have
found a greater proportion identiﬁed with the nares alone
compared with our study in PLWH and conﬁrmed that sampling
multiple anatomic sites greatly increases screening sensitivity.
Within general populations on hospital or intensive care unit
admission, nares cultures were identiﬁed from only about 66%24 to
81.5%25 of all MRSA-colonized patients. Sensitivity analysis has
shown that sampling multiple sites can increase yield with nares
and perineum to 89.6%26 and with nares, throat, and groin
screening to 98%.27 Screening nares only when MRSA prevalence is
low (<6%) yields 68% of all colonized patients; with high preva-
lence it yields 73%; and in the intensive care unit it yields 75%.28
Even with a very high (15.4%) prevalence in our study of PLWH,
the proportion identiﬁed through nares alone (58.9%) was much
lower than proportions identiﬁed in the general population. It is
clear that among PLWH, screening multiple body sites is of even
greater importance.
MRSA colonization remains common among PLWH, and pre-
dictors of colonization are highly variable depending on the clinical
context and study sample characteristics. We found clear differ-
ences in a number of socioeconomic and health indicators between
the 2 clinic sites as seen in Table 1. The GSS serves a primarily white,
more-educated, male population with higher incomes and greater
CD4þ T cell counts compared with the Moore Clinic’s primarily
inner-city, black, less-educated clients with lower incomes and
lower CD4þ T cell counts. However, the choice of the GEE method
for modeling associations can help to account for intraclinic cor-
relations. In addition, both clinics are part of the same medical
service and share the same clinicians, which likely limits differ-
ences in service delivery as a factor in the associations we found.
In this cross-sectional analysis, we identiﬁed the importance of
multibody site evaluation in this patient population and uncovered
additional risk associated with colonization in this group. It is time
for hospital epidemiologists and infection preventionists to
reconsider surveillance approaches for populations known to have
a high colonization prevalence for MRSA.
Limitations
Although robust estimation of SEs was used in ﬁt of the GEE
models, the small number of clinic sites likely resulted in an un-
derestimation of the SEs. Using a cross-sectional method, this study
examined prevalence of MRSA at a single point in time and does not
account for changing relationships among risk factors and MRSA
acquisition over time. We attempted to reduce the likelihood of
providing socially desirable responses, particularly regarding drug
use and sexual behaviors, by using previously implemented survey
questions, providing a private interview location, and conﬁrming
conﬁdentiality of responses. To control for this potential bias,
respondent answers were veriﬁed by medical record review and
abstraction. Sample size was determined based on an estimated
18% prevalence of current abscess; however, prevalence in the
study sample was 7.8% overall. Consequently, our ability to detect
smaller effect sizes and the likelihood that statistically signiﬁcant
associations reﬂect true effects may be limited.
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